Abstract: In some embodiments of the invention, inventive compounds (e.g., Formula (I), (IA), (II), and (III), and urolithin derivatives) are disclosed. Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

Abstract: Compounds for treating tuberculosis and, particularly, anti-tubercular compounds that are (6-methyl-4-substitutedphenyl-2-oxo/thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)(piperidin-1-yl)methanones and their use as anti-tubercular agents are provided.

Abstract: Compounds for treating preventing malaria and, particularly, to larvicidal agents that are 7-isopropyl 1-ethyl/methyl 3-(substituted benzoyl)-2-substituted indolizine-1,7-dicarboxylates derivatives and their use as larvicidal agents.

Abstract: Novel 7-isopropyl 1,2-dimethyl 3-(substituted benzoyl)indolizine-1,2,7-tricarboxylates compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The 7-isopropyl 1,2-dimethyl 3-(substituted benzoyl)indolizine-1,2,7-tricarboxylates compounds, identified as adenosine A3 receptor (A3AR) modulators, are useful as anti-inflammation, anticancer and/or anti-ischemic agents, and as agents for treating other adenosine overexpression related conditions including rheumatoid arthritis, psoriasis and fatty liver diseases, inflammation, pain, and number of pathological conditions of the central and peripheral nervous systems.

Abstract: Adenosine receptor active compounds including 1,2,3,6,8-pentasubstituted indolizines and methods of using the same for inhibiting adenosine receptor activity are provided. These methods can be used to treat one or more pathological conditions of the central and peripheral nervous systems, such as but not limited to allergies, inflammation, glaucoma, brain ischemia, renal fibrosis, cancer, rheumatoid arthritis, psoriasis fatty liver diseases, stroke, pain, and any combination thereof.

Abstract: Compounds for treating tuberculosis and, particularly, to anti-tubercular compounds that are substituted 7-amino-3-(substituted benzoyl)indolizine-1-carboxylates and their use as anti-tubercular agents.

Abstract: Compounds for treating tuberculosis and, particularly, to anti-tubercular compounds that are 1-(2-(substitutedphenyl)-2-oxoethyl)-3,5-dimethylpyridin-1-ium bromides and their use as anti-tubercular agents.

Abstract: Compounds for treating tuberculosis and, particularly, anti-tubercular compounds that are ethyl 2-substitued-1-(substitutedbenzoyl)-7-methylpyrrolo[1,2-a]quinoline-3-carboxylate derivatives and their use as anti-tubercular agents are provided.

Abstract: Compounds for treating tuberculosis and, particularly, antitubercular compounds that are substituted 7-methyl quinoline derivatives and their use as antitubercular agents are provided.

Abstract: Compounds for treating tuberculosis and, particularly, antitubercular compounds that are 1-substituted benzoyl-4-bromopyrrolo[1,2-a]quinoline-3-carboxylate derivatives and their use as antitubercular agents are provided.

Abstract: Novel 1-(2-(substituted phenyl)-2-oxoethyl)-4-(isopropoxycarbonyl)pyridin-1-ium bromide derivatives, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The 1-(2-(substituted phenyl)-2-oxoethyl)-4-(isopropoxycarbonyl)pyridin-1-ium bromide derivative compounds are useful as anti-tubercular agents.

Abstract: Compounds for treating tuberculosis and, particularly, anti-tubercular compounds that are (6-methyl-4-substitutedphenyl-2-oxo/thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)(piperidin-1-yl)methanones and their use as anti-tubercular agents are provided.

Abstract: Compounds for treating tuberculosis and, particularly, to anti-tubercular compounds that are phenyl quinolin-1-ium bromide derivatives and their use as anti-tubercular agents.

Abstract: Compounds for treating tuberculosis and, particularly, anti-tubercular compounds that are ethyl 2-substituted-1-(substitutedbenzoyl)-7-methylpyrrolo[1,2-a]quinoline-3-carboxylate derivatives and their use as anti-tubercular agents are provided.

Abstract: The substituted indolizine dicarboxylates are antibacterial agents. The emergence of drug-resistant bacteria calls for constant development of new antibacterial agents with the aim of generating medicaments that are potent against drug sensitive and resistant bacteria and are well tolerated. The present compounds are not only new, but have very valuable antimicrobial properties. These compounds showed a broad spectrum of activity against tuberculosis mycobacteria. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.

Abstract: Anti-tubercular compounds include trisubstituted indolizines having the following structural formula: wherein R1 is selected from the group consisting of 4-OCH3, 4-Cl, 4-Br, 4-F, 2-NO2, 3,5-CF3, CN, CH3, R2 is COOCH3, COOC2H5, and R3 is H and COOCH3.

Abstract: In some embodiments of the invention, inventive compounds (e.g., Formula (I), (IA), (II), and (III), and urolithin derivatives) are disclosed. Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.